The COVID-19 pandemic has transformed the business landscape across the health care and life sciences industries, and continues to do so. In this unprecedented year, Ropes & Gray has delivered the expertise and intellectual heft that our clients needed to confront the pandemic. Our health care and life sciences practice has stood out this year as being the leading legal adviser in these sectors and received multiple awards recognising that, some examples of which are set out in this newsletter.
The strength of our health care and life sciences practice, together with our market-leading private equity practice, places us in a unique position as the preeminent law firm for PE funds investing in these sectors.
Out of the London office, we acted for clients investing in, amongst other things, vaccine manufacturing sites, cancer diagnostics and treatment, pharmaceutical services, and direct-to-consumer products and sales. We believe that there is a great deal of opportunity for investors as a result of the changing landscape.
We look forward to working with you this year.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.